Specialty biopharmaceutical company developing sustained-release drug delivery systems for ocular conditions.
EyePoint Pharmaceuticals, Inc., headquartered in Watertown, Massachusetts, is a pharmaceutical company dedicated to advancing therapeutics aimed at improving the lives of patients grappling with severe eye disorders. The company specializes in developing and commercializing innovative treatments that address critical needs in ophthalmology.
EyePoint Pharmaceuticals' current portfolio includes YUTIQ, designed for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Additionally, DEXYCU is another commercial product offering targeted relief for postoperative inflammation. These treatments underscore the company's commitment to providing effective solutions for complex eye conditions.
Central to EyePoint Pharmaceuticals' innovation is its proprietary Durasert technology, which enables sustained intraocular drug delivery. Leveraging this platform, the company is advancing its pipeline with EYP-1901, an investigational intravitreal treatment currently undergoing Phase 2 clinical trials. This initiative aims to further expand treatment options and enhance therapeutic outcomes for patients.
Founded in 2000 as pSivida Corp., the company rebranded as EyePoint Pharmaceuticals, Inc. in March 2018 to reflect its focus on ophthalmic pharmaceuticals and sustained drug delivery technologies. With a robust foundation in scientific research and development, EyePoint Pharmaceuticals continues to lead advancements in eye care, addressing unmet medical needs and striving to improve vision health worldwide.